3 research outputs found
Baseline <sup>18</sup>F-FDG PET and CT tumor response measurements with PERCIST and EORTC criteria and progression-free survival per patient with ALK positive NSCLC.
<p>Baseline <sup>18</sup>F-FDG PET and CT tumor response measurements with PERCIST and EORTC criteria and progression-free survival per patient with ALK positive NSCLC.</p
<sup>18</sup>F-FDG maximum intensity projection of patient 2 and 8 prior to (A, B) and after 6 weeks of treatment with crizotinib (C, D).
<p>Scale is from 0–15 SUV. These images illustrate the clinically dramatic decrease in <sup>18</sup>F-FDG uptake, with both patients having a PMR according to both PERCIST criteria and the EORTC recommendations.</p